StockData
Aligos Therapeutics, Inc. logo

Aligos Therapeutics, Inc. (ALGS) stock

ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/3053% below fair value
$1.30−0.06 (-4.41%)

Close on Nov 18, 2026Market cap $16.24MP/E –Yield –

Aligos Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Aligos Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $3.74M, up 19.4% year over year. For fiscal 2025 it was $2.19M, down 39.5% from the year before. The highest annual figure on record is $6.19M in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.19M-39.5%
FY2024Dec 31, 2024$3.61M-41.7%
FY2023Dec 31, 2023$6.19M–
FY2022Dec 31, 2022$0–
FY2021Dec 31, 2021$0–
FY2020Dec 31, 2020$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0-100.0%
Q1 FY2026Mar 31, 2026$2.83M+810.0%
Q4 FY2025Dec 31, 2025$169.00K-72.1%
Q3 FY2025Sep 30, 2025$741.00K-40.7%
Q2 FY2025Jun 30, 2025$965.00K-9.0%
Q1 FY2025Mar 31, 2025$311.00K-55.2%
Q4 FY2024Dec 31, 2024$606.00K-9.8%
Q3 FY2024Sep 30, 2024$1.25M+15.2%
Q2 FY2024Jun 30, 2024$1.06M-75.3%
Q1 FY2024Mar 31, 2024$694.00K+395.7%
Q4 FY2023Dec 31, 2023$672.00K–
Q3 FY2023Sep 30, 2023$1.09M–
Q2 FY2023Jun 30, 2023$4.29M–
Q1 FY2023Mar 31, 2023$140.00K–
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$0–
Q2 FY2022Jun 30, 2022$0–

More Aligos Therapeutics figures

See a number that looks wrong?